{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:05:25Z","timestamp":1791644725396,"version":"4.3.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate uesd for the treatment of HER2- positive (HER2+)breast cancer. This systematic review aimed to evaluate the efficacy and safety of T-DXd in advanced HER2-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PubMed, Web of Science and Embase databases were searched for literature on trastuzumab deruxtecan treatment for HER2-positive or low-expression breast cancer before December 30, 2024. The outcome measures were progression-free survival (PFS), overall survival (OS), objective response rates, and adverse events of any grade and grade\u2005\u2265\u20053. Meta-analysis of the relevant data was performed using Stata 14.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 2995 patients from 7 studies were included. The median PFS and median overall survival of patients in the T-DXd group were significantly longer than those of patients in the control group (mPFS HR\u2005=\u20050.43;95% CI:0.31\u20130.62, p&lt;0.05; mOS HR\u2005=\u20050.72; 95% CI:0.64\u20130.82, p&lt;0.05). Further subgroup analyses based on differences in hormone receptor expression, occurrence of brain metastases, visceral basal conditions, and previous lines of treatment showed that all patients in the T-DXd group had significantly longer mPFS than those in the control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). The objective remission rate of patients in the T-DXd group was significantly higher than that of patients in the control group (RR\u2005=\u20052.31; 95%CI: 1.88\u20132.85, P&lt;0.05). In addition, the T-DXd also increased the incidence of adverse events such as anemia, nausea, vomiting, constipation and interstitial lung disease, but the incidence of neutropenia, diarrhea, and alopecia was not significantly different between the 2 groups. No significant publication bias was observed in this study. The results of the sensitivity analysis showed high heterogeneity in mPFS, but the results obtained after excluding the DESTINY-Breast04 studies were all more robust.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>T-DXd has significant long-term and near-term efficacy in prolonging median overall survival, median PFS, and increasing the objective remission rate in patients with HER2-positive or low-expression breast cancer; however, the treatment is associated with notable adverse events, and physicians should be alert to the occurrence of serious adverse events when using this drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045936","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:01:06Z","timestamp":1763154066000},"page":"e45936","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9962-9612","authenticated-orcid":false,"given":"Yujing","family":"Mu","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Third Afiliated Hospita of Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Third Afiliated Hospita of Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Third Afiliated Hospita of Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Third Afiliated Hospita of Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251121","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251121","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7150\/jca.4925","article-title":"Treating breast cancer in the 21st century: emerging biological therapies.","volume":"4","author":"Tinoco","year":"2013","journal-title":"J Cancer"},{"key":"R3-20251121","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R4-20251121","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clbc.2018.01.006","article-title":"The global need for a trastuzumab biosimilar for patients with HER2-positive breast cancer.","volume":"18","author":"Blackwell","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"R5-20251121","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"R6-20251121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CAD.0b013e328352d292","article-title":"Recent advances in novel targeted therapies for HER2-positive breast cancer.","volume":"23","author":"Murphy","year":"2012","journal-title":"Anticancer Drugs"},{"key":"R7-20251121","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval.","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"R8-20251121","doi-asserted-by":"crossref","first-page":"102639","DOI":"10.1016\/j.dnarep.2019.102639","article-title":"DNA Damage by an essential enzyme: a delicate balance act on the tightrope.","volume":"82","author":"Nitiss","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"R9-20251121","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1248\/bpb.30.2365","article-title":"Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.","volume":"30","author":"Shiose","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"R10-20251121","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1021\/acsomega.9b00430","article-title":"Study on the heterogeneity of T-DM1 and the analysis of the unconjugated linker structure under a stable conjugation process.","volume":"4","author":"Wu","year":"2019","journal-title":"ACS Omega"},{"key":"R11-20251121","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers16040800","article-title":"Next-generation HER2-targeted antibody-drug conjugates in breast cancer.","volume":"16","author":"Zimmerman","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R12-20251121","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R13-20251121","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R14-20251121","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument.","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R15-20251121","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R16-20251121","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R17-20251121","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"key":"R18-20251121","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"R19-20251121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"R20-20251121","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"R21-20251121","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"R22-20251121","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"R23-20251121","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"R24-20251121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"R25-20251121","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer.","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"R26-20251121","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis.","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"R27-20251121","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates(ADCs)in HER2-positive breast cancer:state of the art and future directions.","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"key":"R28-20251121","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"R29-20251121","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1016\/j.annonc.2022.03.181","article-title":"1620 Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer.","volume":"33","author":"Hamilton","year":"2022","journal-title":"Ann Oncol"},{"key":"R30-20251121","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"R31-20251121","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"R32-20251121","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:02:21Z","timestamp":1763766141000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000045936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":32,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045936","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-05-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}